"Friedreich's Ataxia Complicated by Diabetes Mellitus: A Case Report on Management Challenges and Sick Day Guidelines"
Abstrakt
Aim: The aim of this report is to highlight the clinical challenges and management considerations for diabetes mellitus (DM) in patients with Friedreich's ataxia (FA), specifically focusing on a case of Friedreich’s ataxia-related diabetes mellitus (FRDA-related DM) complicated by diabetic ketoacidosis (DKA).
Background: Friedreich's ataxia (FA) is a rare, inherited neurodegenerative disorder that manifests with progressive ataxia, muscle weakness, and cardiomyopathy. Diabetes mellitus is a common comorbidity in FA, with both genetic and metabolic factors contributing to insulin resistance and beta-cell dysfunction. The clinical presentation of FRDA-related DM and its management remain underexplored in the literature.
Case Description: An 11-year-old male diagnosed with DM at age 10 presented with diabetic ketoacidosis (DKA) following a viral illness. His clinical history included a progressive neurological disorder, which on evaluation, was consistent with FA. The patient’s condition had worsened over time, with increasing ataxia, hypertrophic cardiomyopathy, and severe motor dysfunction, resulting in a bedridden state. The patient’s DKA episode was attributed to poor adherence to insulin therapy and a lack of knowledge regarding sick-day management.
Conclusion: Diabetes is a common and challenging comorbidity in Friedreich's ataxia. Multidisciplinary care, including education on treatment adherence and sick-day management, is crucial in preventing complications. Further research is needed to establish comprehensive management strategies for FRDA-related DM.
Clinical Significance: This case highlights the need for tailored care in FA patients with diabetes, addressing both the neurological and metabolic aspects of the disease to optimize patient outcomes.
##plugins.generic.usageStats.downloads##
Bibliografia
2. Tanaka H. [Friedreich ataxia with GAA repeat expansion: molecular mechanism and clinical feature]. Nihon Rinsho. 1999 Apr;57(4):960-6.
3. Hanley A, Corrigan R, Mohammad S, MacMahon B. Friedreich's ataxia cardiomyopathy: case based discussion and management issues. Ir Med J. 2010 Apr;103(4):117-8.
4. Delatycki MB, Bidichandani SI. Friedreich ataxia- pathogenesis and implications for therapies. Neurobiol Dis. 2019 Dec;132:104606.
5. Palau F. Friedreich's ataxia and frataxin: molecular genetics, evolution and pathogenesis (Review). Int J Mol Med. 2001 Jun;7(6):581-9.
6. Cnop M, et al. Central role and mechanisms of beta-cell dysfunction and death in friedreich ataxia-associated diabetes. Annals of neurology. 2012;72(6):971–82.
7.Greeley NR, et al. Cross-sectional analysis of glucose metabolism in Friedreich ataxia. Journal of the neurological sciences. 2014;342(1-2):29–35
8.McCormick A, et al. Impact of diabetes in the Friedreich ataxia clinical outcome measures study. Annals of clinical and translational neurology. 2017;4(9):622–31
9. Cnop M, Mulder H, Igoillo-Esteve M. Diabetes in Friedreich ataxia. J Neurochem 2013;126(Suppl 1):94–102.
10. Igoillo-Esteve M, Gurgul-Convey E, Hu A, Romagueira Bichara Dos Santos L, Abdulkarim B, Chintawar S, et al. Unveiling a common mechanism of apoptosis in beta-cells and neurons in Friedreich’s ataxia. Hum Mol Genet 2015;24:2274–86
11. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697-708.
12. American Diabetes Association. 7. Diabetes technology: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S85-S99.
13. Tamaroff J, DeDio A, Wade K, Wells M, Park C, Leavens K, et al. Friedreich’s ataxia related diabetes: Epidemiology and management practices. Diabetes Res Clin Pract. 2022;186:109828
14. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30(11):2773-8
15. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2016;375(19):1834-44.
16. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008.
17. Laffel LM, Limbert C, Phelan H, et al. ISPAD Clinical Practice Consensus Guidelines 2018: sick day management in children and adolescents with diabetes. Pediatr Diabetes. 2018;19(suppl 27):193–204

Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa 4.0 Międzynarodowe.
